Wide Open Agriculture (ASX:WOA) Extends Univar’s Exclusive China Lupin Protein Rights to 2028

Sonal Goyal

27 October 2026 12:13 PM AEDT

Wide Open Agriculture (ASX:WOA) Extends Univar’s Exclusive China Lupin Protein Rights to 2028

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Univar’s exclusive right to distribute WOA’s lupin protein in mainland China now runs to 31 December 2028.
Univar must purchase at least 50 tonnes within 12 months of commercial supply becoming available to keep exclusivity.
The agreement has no immediate financial impact, and revenue will arise only once commercial supply is restored and pricing is agreed.
WOA is transitioning to contract manufacturing after winding down its German facility.

Wide Open Agriculture Ltd (ASX:WOA) announced on 27 October 2026 that it has extended its Offtake and Distribution Agreement with Univar Solutions China, moving the end of Univar’s exclusive right to market and distribute its lupin protein products in mainland China to 31 December 2028.

Background to the Extension

The original agreement, announced on 30 April 2025, appointed Univar as exclusive distributor of WOA’s lupin protein products in mainland China and required Univar to purchase a minimum of 50 tonnes of lupin protein isolate over a 12-month period. Since then, Univar has completed customer trials and confirmed its commercial rollout strategy for China.

WOA is moving to contract manufacturing and has wound down its German facility, so commercial product was not available to Univar within the original timeframe. Both parties said they remain committed to developing and commercialising lupin-based ingredients in China, and agreed to extend the term.

Key Terms of the Extended Agreement

Exclusivity continues to 31 December 2028, subject to Univar meeting its marketing commitments, which include customer engagement, market development and product application trials, depending on the availability of samples. If Univar materially fails to meet them, WOA may, after 30 days’ written notice and an opportunity to remedy, convert the distribution right to non-exclusive.

The 50-tonne minimum purchase remains a condition of exclusivity, but the 12-month period will now begin when WOA notifies Univar in writing that commercial quantities are available. WOA is progressing arrangements to restore commercial supply and will keep Univar informed. The agreement does not oblige WOA to begin supply by a specified date, and all other terms are unchanged.

Why This Could Matter

The extension keeps the China distribution arrangement in place while supply is rebuilt. The company states that the agreement is not a purchase order and has no immediate financial impact, and that no revenue will be received from Univar until supply is restored and pricing is agreed. The timing of any sales therefore depends on the contract manufacturing arrangements.

Final Takeaway

WOA and Univar have kept their China lupin protein agreement alive to the end of 2028, with exclusivity tied to a minimum purchase that starts only once product is available. No supply date has been set, and no revenue is expected until supply is restored.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.